fbpx Skip to main content

Member's Profile

MEI Pharma

11455 El Camino Real Ste 250
San Diego,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2010
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About MEI Pharma
Biotech Company
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for the treatment of cancer. The Company’s clinical development pipeline includes two proprietary isoflavone-based drug candidates, ME-143 and ME-344, and a potential best-in-class, oral histone deacetylase (HDAC) inhibitor, Pracinostat. Results from a Phase I dose-escalation trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 212.
Related News
No related news posted by this Member